CD45RB is a novel molecular therapeutic target to inhibit Abeta peptide-induced microglial MAPK activation.
Microglial activation, characterized by p38 MAPK or p44/42 MAPK pathway signal transduction, occurs in Alzheimer's disease (AD). Our previous studies demonstrated CD45, a membrane-bound protein tyrosine phosphatase (PTP), opposed beta-amyloid (Abeta) peptide-induced microglial activation via in...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2008-05-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC2366070?pdf=render |